Pfizer
Changing direction
Pfizer subsidiary dumps direct distribution model to return to CSO wholesale deliveries Upjohn Australia, a subsidiary of Pfizer, has announced that it will distribute its medicines through Community Service Obligation …
Merger confirmed
A new market leader in a range of OTC healthcare categories has been announced Pharmaceutical giants Pfizer and GSK have confirmed they have closed the transaction to create a new …
ACCC vs Pfizer case comes to a close
The High Court has dismissed the ACCC’s application for special leave to appeal in its case against Pfizer Australia over the sale of atorvastatin This month the Australian Competition and …
ACCC loses appeal bid
The High Court has dismissed the ACCC’s application for special leave to appeal the Full Federal Court decision in a case against Pfizer In early 2012, Pfizer offered significant discounts …
Who’s earning the big money?
New list reveals the world’s top 25 pharma companies by market capitalisation A new report from Global Data has revealed the 25 leading global pharmaceutical manufacturers in order of their …
ACCC still has Pfizer in its sights
The ACCC is seeking special leave to appeal the dismissal of its allegations against Pfizer Australia The Australian Competition and Consumer Commission is seeking leave from the High Court to …
In the name of competition
ACCC loses its appeal against a ruling rejecting a case over Pfizer’s steps to secure pharmacy business The Federal Court of Australia has rejected an appeal by the Australian Competition …
EpiPen supply issues to continue indefinitely
While Pfizer is working to achieve ongoing availability, it reportedly cannot commit to a specific time when the supply constraint will be fully resolved Mylan/Alphapharm, the sponsor of EpiPens, has …
Why a drug treatment for dementia has eluded us
Pfizer has announced it will stop research into developing drugs to treat Alzheimer’s disease, after costly failed attempts over the past decade Jürgen Götz, Director, Clem Jones Centre for Ageing Dementia …
Mixup wasn’t us: Pfizer
Pfizer has confirmed that the Heparin-Lignocaine mixup occurred at one pharmacy, not its own facilities But the recall for Heparin Injection 5000 IU 5mL x 50 and Lignocaine Injection 1% …
Heparin and Lignocaine recall, isolated incident likely
The TGA and Pfizer are working on a recall for Heparin and Lignocaine ampoules following a reported product mix-up The TGA said in a statement on Monday (14 August) that …
Cap problem leads to recall
Anticonvulsant recalled due to issue with child-resistant caps Pfizer Australia, in consultation with the TGA, has initiated a recall for product correction for bottles of phenytoin 30 mg capsules, 100 …